PharmaPhorum published an article by Olga Romanova, engagement manager at DataArt, about practical GenAI use cases in clinical trials and the most prevalent concerns surrounding this technology.
“The process of developing a new drug can take up to 12 years and cost an estimated $2.3 billion, and yet 90% of clinical trials fail. The reasons for this are often poor patient cohort selection, recruiting tactics, and insufficient infrastructure. Generative AI can help conduct faster, better-optimised clinical trials and potentially increase efficiency across various areas.”
“Generative AI can significantly enhance various areas of clinical trials, including data gathering, patient engagement, knowledge processing, and document creation. Despite legitimate concerns about it among healthcare professionals, continual refinement and ongoing supervision can help mitigate potential risks.”
You can read the full article here.
